MDWD: MediWound Ltd. - Summary | Jitta

MediWound Ltd.

NASDAQ:MDWD

Price
$14.22
Loss Chance
58.3%
0.61JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
647 / 715
3,980 / 4,224
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (32)
Recent Business Performance (22)
Financial Strength (46)
Return to Shareholders (1)
Competitive Advantage (10)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 2056.75% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.61
100.00%
3.03
208.13%
3.05
162.56%
Pharmaceuticals
4.95
54.89%
5.05
81.56%
5.69
90.01%
COMPANY DESCRIPTION
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.